-
-
-
-
-
-
-
Madrigal Pharmaceuticals (MDGL) Reiterated at Market Outperform by Citizens
-
-
-
-
-
-
-
Wolfe Research comments on Madrigal Pharmaceuticals (MDGL) M&A optimism 'makes strategic sense' for buyers
-
-
-
-
-
-
-
B.Riley Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)
-
-
-
-
-
-
-
Madrigal Pharmaceuticals (MDGL) PT Raised to $620 at H.C. Wainwright
-
-
-
-
-
-
-
Cantor Fitzgerald Upgrades Madrigal Pharmaceuticals (MDGL) to Overweight, 'clarity on 2026 growth and no major near-term headwinds for the stock'
-
-
-
-
-
-
-
UBS Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL) as Management Confident in MASH Market Opportunity
-
-
-
-
-
-
-
Madrigal gets EU approval for first MASH treatment Rezdiffra
-
432,296 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

